Cargando…

Atypical Chemokine Receptor 1 polymorphism cannot be used as an indicator of liver fibrosis progression in Hepatitis C virus positive patients

BACKGROUND & OBJECTIVE: Atypical chemokine receptor 1(ACKR1) represents an atypical chemokine receptor that can bind promiscuously to various chemokines. Chemokines play a crucial role to recruit leukocyte subsets migration through the endothelium and into liver against the virus during the prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Lin-Nan, Zhang, Shu-Ting, Zhou, Shi-Hang, Yu, Wei-Jian, Liu, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673721/
https://www.ncbi.nlm.nih.gov/pubmed/29142552
http://dx.doi.org/10.12669/pjms.335.12590
_version_ 1783276628626898944
author Shao, Lin-Nan
Zhang, Shu-Ting
Zhou, Shi-Hang
Yu, Wei-Jian
Liu, Ming
author_facet Shao, Lin-Nan
Zhang, Shu-Ting
Zhou, Shi-Hang
Yu, Wei-Jian
Liu, Ming
author_sort Shao, Lin-Nan
collection PubMed
description BACKGROUND & OBJECTIVE: Atypical chemokine receptor 1(ACKR1) represents an atypical chemokine receptor that can bind promiscuously to various chemokines. Chemokines play a crucial role to recruit leukocyte subsets migration through the endothelium and into liver against the virus during the progression of hepatitis C virus (HCV) infection. Most HCV positive patients can lead to liver fibrosis. Hyaluronic acid (HA), laminin (LN), collagen IV(C-IV) and amino-terminal pro-peptide of Type-III pro-collagen (PIII NP) are indices of the extent of liver fibrosis. The aim of this study was to investigate the association between ACKR1 polymorphism and liver fibrosis with these four serum liver markers in HCV positive patients. METHODS: From April 2015 to December 2015, a total of 210 patients (109 males and 101 females) with chronic HCV infection at Dalian Infectious Hospital were recruited to participate in this study. ACKR1 genotyping was using TaqMan probes method. HA, LN, C-IV and PIII NP were detected by using diagnostic kits. RESULTS: We compared serum levels of HA, LN, C-IV and PIII NP between FY(*)A/FY(*)A and FY(*)A/FY(*)B patients and the differences were not significant (P=0.905, P=0.298, P=0.880 and P=0.470, respectively). CONCLUSIONS: This study has attempted to elucidate the role of ACKR1 polymorphism in liver fibrosis progression of HCV infection, our results demonstrated that ACKR1 polymorphism is not directly associated with the fibrogenesis in HCV positive patients.
format Online
Article
Text
id pubmed-5673721
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Professional Medical Publications
record_format MEDLINE/PubMed
spelling pubmed-56737212017-11-15 Atypical Chemokine Receptor 1 polymorphism cannot be used as an indicator of liver fibrosis progression in Hepatitis C virus positive patients Shao, Lin-Nan Zhang, Shu-Ting Zhou, Shi-Hang Yu, Wei-Jian Liu, Ming Pak J Med Sci Original Article BACKGROUND & OBJECTIVE: Atypical chemokine receptor 1(ACKR1) represents an atypical chemokine receptor that can bind promiscuously to various chemokines. Chemokines play a crucial role to recruit leukocyte subsets migration through the endothelium and into liver against the virus during the progression of hepatitis C virus (HCV) infection. Most HCV positive patients can lead to liver fibrosis. Hyaluronic acid (HA), laminin (LN), collagen IV(C-IV) and amino-terminal pro-peptide of Type-III pro-collagen (PIII NP) are indices of the extent of liver fibrosis. The aim of this study was to investigate the association between ACKR1 polymorphism and liver fibrosis with these four serum liver markers in HCV positive patients. METHODS: From April 2015 to December 2015, a total of 210 patients (109 males and 101 females) with chronic HCV infection at Dalian Infectious Hospital were recruited to participate in this study. ACKR1 genotyping was using TaqMan probes method. HA, LN, C-IV and PIII NP were detected by using diagnostic kits. RESULTS: We compared serum levels of HA, LN, C-IV and PIII NP between FY(*)A/FY(*)A and FY(*)A/FY(*)B patients and the differences were not significant (P=0.905, P=0.298, P=0.880 and P=0.470, respectively). CONCLUSIONS: This study has attempted to elucidate the role of ACKR1 polymorphism in liver fibrosis progression of HCV infection, our results demonstrated that ACKR1 polymorphism is not directly associated with the fibrogenesis in HCV positive patients. Professional Medical Publications 2017 /pmc/articles/PMC5673721/ /pubmed/29142552 http://dx.doi.org/10.12669/pjms.335.12590 Text en Copyright: © Pakistan Journal of Medical Sciences http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Shao, Lin-Nan
Zhang, Shu-Ting
Zhou, Shi-Hang
Yu, Wei-Jian
Liu, Ming
Atypical Chemokine Receptor 1 polymorphism cannot be used as an indicator of liver fibrosis progression in Hepatitis C virus positive patients
title Atypical Chemokine Receptor 1 polymorphism cannot be used as an indicator of liver fibrosis progression in Hepatitis C virus positive patients
title_full Atypical Chemokine Receptor 1 polymorphism cannot be used as an indicator of liver fibrosis progression in Hepatitis C virus positive patients
title_fullStr Atypical Chemokine Receptor 1 polymorphism cannot be used as an indicator of liver fibrosis progression in Hepatitis C virus positive patients
title_full_unstemmed Atypical Chemokine Receptor 1 polymorphism cannot be used as an indicator of liver fibrosis progression in Hepatitis C virus positive patients
title_short Atypical Chemokine Receptor 1 polymorphism cannot be used as an indicator of liver fibrosis progression in Hepatitis C virus positive patients
title_sort atypical chemokine receptor 1 polymorphism cannot be used as an indicator of liver fibrosis progression in hepatitis c virus positive patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673721/
https://www.ncbi.nlm.nih.gov/pubmed/29142552
http://dx.doi.org/10.12669/pjms.335.12590
work_keys_str_mv AT shaolinnan atypicalchemokinereceptor1polymorphismcannotbeusedasanindicatorofliverfibrosisprogressioninhepatitiscviruspositivepatients
AT zhangshuting atypicalchemokinereceptor1polymorphismcannotbeusedasanindicatorofliverfibrosisprogressioninhepatitiscviruspositivepatients
AT zhoushihang atypicalchemokinereceptor1polymorphismcannotbeusedasanindicatorofliverfibrosisprogressioninhepatitiscviruspositivepatients
AT yuweijian atypicalchemokinereceptor1polymorphismcannotbeusedasanindicatorofliverfibrosisprogressioninhepatitiscviruspositivepatients
AT liuming atypicalchemokinereceptor1polymorphismcannotbeusedasanindicatorofliverfibrosisprogressioninhepatitiscviruspositivepatients